Overview of Paragis

Quick Facts

Property	Description
Active ingredient	Paracetamol (Acetaminophen)
Form	Oral tablet, Oral suspension, Capsule
Pharmacological class	Analgesic (Pain reliever), Anti-pyretic (Fever reducer)
Common use	Symptomatic relief of pain and fever
Origin	Synthetic (P-Aminophenol Derivative)

What is Paragis and What Type of Medicine is It?

The medication known as Paragis is a brand name for a widely utilized, synthetic pharmaceutical product containing the active substance Paracetamol, which is also recognized internationally as Acetaminophen. This compound is functionally classified as a Miscellaneous Analgesic and an Anti-pyretic, placing it in the drug class primarily used for the management of pain and elevated body temperature. Its chemical structure is that of a P-Aminophenol Derivative, and it is notably deficient in significant peripheral anti-inflammatory activity, a key distinction from Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Composition, Origin, and Available Forms

The core of Paragis is the active substance Paracetamol, which is an entirely synthetic compound manufactured through established chemical processes. Paracetamol is globally recognized as an essential medicine and is commonly utilized as a therapy for pain. The clinical recognition of the drug underscores its established utility in providing relief from common ailments. It is primarily delivered via the oral route in several common forms, including the oral tablet, oral suspension, and capsule. While many Paracetamol products are identical generics, brands like Paragis often have specific dosage strengths or may be integrated into a fixed-dose combination product with another agent.

What is the General Therapeutic Purpose of Paragis?

The fundamental therapeutic purpose of Paragis is concentrated on providing effective, symptomatic relief from pain and achieving fever reduction. For example, it is commonly used to ease the general discomfort associated with a headache or to lower body temperature during a bout of the common cold. Its designation as an analgesic means it is utilized to increase the body's threshold for discomfort, while its anti-pyretic action targets the thermoregulatory control center in the brain to help normalize body temperature. The drug’s primary effects are mediated within the central nervous system, making it a medicine used for the symptomatic management of these two core manifestations.

Regulatory References

Therapeutic Uses of Paragis

What Paragis Treats: Main Uses and Benefits

Paragis is commonly used for symptomatic relief, applied across domains where additional symptomatic support is needed. Its therapeutic utility is recognized for managing pain relief and temperature reduction. It serves as a foundation for supportive care across numerous acute and episodic manifestations.

It is relevant for easing symptoms such as common headache, minor toothache, musculoskeletal aches, and period pain (dysmenorrhea), and is commonly used for the generalized aches associated with the common cold or influenza. This broad applicability means: “The medication supports patients by easing a range of common discomforts that interfere with daily comfort.”

Quick Fact: Use for Acute Discomfort and Fever

Paragis is used in settings marked by temporary physiological imbalance and is applied in addressing an abnormally high body temperature. It is relevant for managing symptoms that interfere with functional stability in children and adults, and may be part of symptomatic management for pain and fever in pregnant and breastfeeding patients. This use helps improve day-to-day comfort during symptomatic periods.

Regulatory References

Therapeutic Goods Administration (TGA) monograph on Paracetamol

Eligibility and Restrictions for Use

The eligibility for using Paragis (Paracetamol/Acetaminophen) is strictly defined by regulatory bodies based on patient-specific factors, organ function, and risk status.

Contraindications and Restrictions

Classification	Population/Condition
Contraindicated (Must Not Use)	Patients with severe hepatic impairment or severe active liver disease. Known hypersensitivity to paracetamol or any excipients.
Restricted Use (Conditional)	Patients with severe renal impairment (CrCl leq 30 mL/min), non-severe hepatic impairment, or chronic alcoholism.

Age and Physiological Eligibility

Use is established for adults and the geriatric population. However, the regulatory status for some formulations is not established for certain young pediatric patients (e.g., under two years of age). Concomitant use with any other paracetamol-containing medicine is prohibited to prevent overdose.

Use during pregnancy is permitted only when clinically necessary, and official guidance emphasizes using the lowest effective dose for the shortest duration. Use is generally permitted during lactation at therapeutic doses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interactions for Paragis (Paracetamol) as specified in regulatory prescribing information, focusing on pharmacokinetic and pharmacodynamic outcomes.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class	Official Interaction Pattern
Oral Anticoagulants (Coumarins)	Chronic, regular co-administration may potentiate the anticoagulant effect (increased INR), which is a clinically significant pharmacodynamic interaction.
Enzyme Inducers (e.g., Phenytoin, Carbamazepine)	These agents may accelerate Paracetamol metabolism, potentially resulting in a decreased therapeutic plasma exposure over time.
Probenecid	Documented to reduce the clearance of Paracetamol by inhibiting conjugation, leading to a substantial increase in Paracetamol plasma concentration.
Zidovudine (AZT)	Concurrent chronic use may increase Zidovudine plasma levels and risk of neutropenia due to decreased metabolism.

Timing and Substance-Specific Constraints

The co-administration of Cholestyramine is officially restricted by time; the substance must be separated by at least one hour from Paracetamol to minimize the documented reduction in Paracetamol absorption. Alcohol (Ethanol) consumption is documented as significantly increasing the risk of hepatotoxicity due to the depletion of protective liver capacity. Furthermore, regulatory documents explicitly restrict co-use with other Paracetamol-containing products due to the severe risk of overdose.

Mechanism of Action

The mechanism of action for Paragis (Eleusine indica) involves modulation of intracellular signaling cascades predominantly within immune and hepatic tissues. Active constituents act as molecular modulators of cellular redox state by directly scavenging various reactive oxygen species (ROS) and free radicals, such as the DPPH radical. This antioxidant interaction maintains cellular integrity and prevents lipid peroxidation of cell membranes.

Concurrently, compounds in E. indica interfere with inflammatory signaling. They function as inhibitors to repress the activation and expression of Tumor Necrosis Factor-alpha (TNF-alpha) and the p38 Mitogen-Activated Protein Kinase (p38 MAPK) pathway. This inhibition of upstream signaling cascades subsequently reduces the systemic release of proinflammatory cytokines and chemokines.

System-level physiological consequences include generalized downregulation of systemic inflammatory markers and enhanced endogenous antioxidant capacity through the preservation of reduced glutathione (GSH) levels within targeted organs, such as the liver. This cascade of events results in a shift toward reduced oxidative cellular stress and attenuated cellular signaling associated with inflammatory responses.

Dosage and Administration Information

How Paragis is Used

Paragis, containing Paracetamol (Acetaminophen), is typically administered via the oral route (tablets, capsules, solutions) for common symptomatic relief, and also through the rectal (suppository) and intravenous (IV) routes for specific clinical needs. Administration is generally conducted on an as-needed basis for the management of pain and fever.

Official Dosing and Administration Constraints

The standard single oral dose for adults is typically 500 mg to 1000 mg (1 g). There is a strict maximum intake to prevent accumulation. The total dosage must not exceed 4000 mg (4 g) in a 24-hour period, inclusive of all co-administered products containing the active substance.

A critical procedural constraint is the minimum dosing interval of at least four hours between administrations. Oral formulations can generally be taken with or without food.

Use Patterns and Population Adjustments

Paragis is primarily intended for short-term use. Patients requiring continuous administration for more than a few days are directed to consult a healthcare professional.

Specific dosage adjustments are stipulated for patients with organ impairment. For those with severe renal impairment, the minimum dosing interval is extended to six or eight hours, based on the degree of impairment. Similarly, a reduction in the maximum daily dose (often to 2000 mg per day or less) is indicated for adults with hepatic impairment or specific risk factors such as chronic alcoholism.

Recent Clinical Evidence

The clinical research for Paragis (Paracetamol) is extensive, focusing primarily on research exploring outcomes related to physical discomfort and systemic imbalance. The evidence largely consists of numerous Randomized Controlled Trials (RCTs) and comprehensive systematic reviews, which contribute to the body of knowledge regarding short-term symptom change.

Evidence for Acute Pain and Fever

Research has examined the use of Paragis in trials applied to conditions characterized by fluctuating or episodic manifestations of pain, such as in study populations experiencing headache or acute musculoskeletal discomfort. Studies observed that the measurements of acute pain intensity in the Paragis group varied compared to those recorded in the placebo groups. The drug was also evaluated in research contexts involving temporary physiological imbalance characterized by an abnormally high body temperature. Studies reported measurements where temperature patterns in the Paragis group varied compared to placebo.

Evidence in Specific Populations and Chronic Use

Paragis was studied for use in children from infancy through adolescence, primarily examining short-term symptom changes related to fever and mild-to-moderate pain. Findings describe patterns suggesting that the use of Paragis was associated with changes in pain and temperature measurements compared to placebo in pediatric groups. However, follow-up durations were limited, meaning there is sparse evidence monitoring long-term patterns.

Research exploring chronic pain is structured differently, applying to conditions marked by functional limitations like low back pain and knee/hip osteoarthritis. For low back pain, large-scale studies reported that the data show patterns where the measurements of pain and disability were observed to be similar between the Paragis group and the placebo group. For osteoarthritis, observed changes in pain intensity were numerically very small in the overall context of the measured outcomes.

Research Gaps and Uncertainty

The evidence base for Paragis largely consists of studies observing responses over defined, short time intervals, focusing on acute changes. Consequently, long-term effects are not fully established through high-quality research exploring maintenance or durability of outcomes. Research highlights that evidence quality varies across studies for chronic pain conditions, and data for certain groups (e.g., those with chronic kidney disease) remain limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Paragis (FAQ)

Q: Is Paragis used primarily for pain relief, fever, or other conditions?

A: Official regulatory documents indicate that Paragis, which contains Paracetamol (Acetaminophen), is used primarily to manage symptoms. Its main established uses are for the relief of mild to moderate pain and for the reduction of fever.

Q: How quickly does Paragis typically start to work when consumed?

A: According to pharmacokinetic information, when taken orally, Paragis is absorbed quickly into the body. Peak plasma concentrations are typically measured within 30 to 60 minutes after an oral dose.

Q: What is the average duration of action or effect of Paragis?

A: The pain-relieving effects of Paragis are generally reported to last for approximately 4 to 6 hours. This duration provides context for the minimum interval between administrations outlined in official guidelines.

Q: What are the most commonly reported side effects when taking Paragis?

A: Official safety documentation focuses on rare but serious adverse reactions, such as allergic reactions, blood disorders, and severe liver problems. Information on the frequency of mild, less serious effects is often generalized.

Q: Is it normal to experience mild nausea or vomiting after taking Paragis?

A: Nausea, vomiting, and appetite loss are sometimes reported, and are listed as potential signs of high exposure or overdose in official warnings. If these symptoms are severe or do not resolve, further consultation may be necessary.

Q: What populations, such as children or the elderly, should use Paragis with caution?

A: Official guidance stresses that certain groups must use this medicine with caution. This includes individuals with pre-existing conditions like severe liver or kidney impairment, or those with chronic alcoholism. Specific guidelines apply to young children, and the use in those under two years of age may not be established for all formulations.

Q: What does the current research evidence say about the anti-inflammatory properties of Paragis?

A: Studies on Paragis (Paracetamol) show that it is classified primarily as an analgesic (pain reliever) and anti-pyretic (fever reducer). It is important to note that, unlike common NSAIDs, official information highlights that Paragis is deficient in significant anti-inflammatory activity in the periphery of the body.

Q: Are there any human clinical trials (not just animal or lab studies) on the efficacy of Paragis?

A: Yes, the effectiveness of Paragis is strongly supported by an extensive body of clinical research. This includes numerous Randomized Controlled Trials (RCTs) and comprehensive systematic reviews, particularly regarding short-term changes in pain and fever symptoms.

Q: Is there a risk of developing a stomach upset or irritation from taking Paragis?

A: While the focus of official warnings is on liver safety, minor stomach upset can occasionally occur. Official patient information notes that oral formulations can be taken with or without food. Taking it with food may be an option to consider if gastric irritation is experienced.

Q: Is it better to take Paragis with food or on an empty stomach?

A: The official administration instructions for oral formulations of Paragis (Paracetamol) generally state that it can be taken either with food or on an empty stomach.

Q: Does Paragis have any effect on blood pressure or heart function?

A: Paragis is not typically associated with the same cardiovascular risks as some other classes of pain medication. Official guidance suggests that individuals with high blood pressure, heart conditions, or those using diuretics review the medicine’s use with a healthcare professional.

Q: Are there different forms of Paragis available, like capsules, tea bags, or raw plant material?

A: Paragis, when referring to the Paracetamol product, is available in multiple regulated forms. These include common oral tablets, capsules, liquid suspensions, and specific clinical forms such as rectal suppositories and intravenous (IV) solutions.

Q: Is Paragis known to cause any skin reactions or rashes?

A: Yes, official safety information indicates that Paragis (Paracetamol) can cause serious, though rare, skin reactions. These include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Q: What is the difference in action between Paragis and a standard NSAID?

A: The key regulatory distinction is their pharmacological class. Paragis is an analgesic and anti-pyretic. Unlike standard NSAIDs (Nonsteroidal Anti-inflammatory Drugs), official information indicates that Paragis is noted for its deficiency in significant anti-inflammatory activity in the periphery of the body.

Q: How should Paragis products be stored to maintain their potency?

A: To ensure the medicine remains stable and effective, official storage rules require it to be kept at a controlled room temperature, typically between 20 C and 25 C. The product must also be protected from excess moisture and heat and kept tightly closed in its original container.

Q: Does Paragis have any effect on energy levels or cause tiredness/fatigue?

A: While tiredness is not commonly reported at therapeutic doses, extreme fatigue or lethargy is a symptom listed in official documents related to potential high exposures or overdose. If unusual or extreme tiredness or fatigue is experienced, it is appropriate to review the situation with a healthcare professional.

Q: Can Paragis be taken if a person is also taking other herbal supplements?

A: Official labeling details interactions with certain prescription medicines and alcohol. However, it does not specifically provide formal safety data or warnings regarding co-administration with non-drug herbal supplements. Therefore, review with a healthcare professional is generally recommended before combining Paragis with other herbal supplements.

Q: Does Paragis interact with common over-the-counter pain relievers like Ibuprofen?

A: Regulatory documents primarily warn against taking Paragis with any other product containing Paracetamol to prevent overdose. While Paracetamol is often used alongside NSAIDs like Ibuprofen, always ensure you are not exceeding the maximum recommended total daily intake from all sources.

How should Paragis be stored and disposed of?

The storage and disposal of Paragis (Paracetamol) are governed by strict official requirements to preserve product stability and ensure public safety.

Storage Requirements

Classification	Official Regulatory Requirement
Temperature Range	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F); do not store above 30 C.
Environmental Protection	Protect the product from excessive heat and moisture and keep it dry.
Container Rules	Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety	Must be stored out of the sight and reach of children (mandatory instruction).

Disposal Instructions

Official disposal rules require that unused or expired Paragis be disposed of according to local regulatory requirements. Disposal via wastewater (flushing down a toilet or sink) is explicitly prohibited to prevent environmental contamination.

Element	Regulatory Statement
Key Adverse Reaction Categories	Blood disorders (thrombocytopenia), Immune system disorders, Hepatobiliary (liver) disorders, and severe cutaneous adverse reactions (SCARs).
Frequency Classification	Adverse reactions are generally Rare or Very Rare when the medicine is taken within the recommended dosage limits.
System-Organ Classes Involved	Immune System, Hepatobiliary, Blood and Lymphatic System, Skin and Subcutaneous Tissue, and Renal/Urinary systems.
Serious Adverse Reactions	Acute liver failure (potentially fatal, especially with overdose), and severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Paragis